Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation

Pavel Burda, Nikola Curik, Juraj Kokavec, Petra Basova, Dana Mikulenkova, Arthur I. Skoultchi, Jiri Zavadil, Tomas Stopka

. 2009 ; 7 (10) : 1693-1703.

Language English Country United States

Document type Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc12009041

Grant support
NR9021 MZ0 CEP Register
NS10310 MZ0 CEP Register

Hematopoietic transcription factors GATA-1 and PU.1 bind each other on DNA to block transcriptional programs of undesired lineage during hematopoietic commitment. Murine erythroleukemia (MEL) cells that coexpress GATA-1 and PU.1 are blocked at the blast stage but respond to molecular removal (downregulation) of PU.1 or addition (upregulation) of GATA-1 by inducing terminal erythroid differentiation. To test whether GATA-1 blocks PU.1 in MEL cells, we have conditionally activated a transgenic PU.1 protein fused with the estrogen receptor ligand-binding domain (PUER), resulting in activation of a myeloid transcriptional program. Gene expression arrays identified components of the PU.1-dependent transcriptome negatively regulated by GATA-1 in MEL cells, including CCAAT/enhancer binding protein alpha (Cebpa) and core-binding factor, beta subunit (Cbfb), which encode two key hematopoietic transcription factors. Inhibition of GATA-1 by small interfering RNA resulted in derepression of PU.1 target genes. Chromatin immunoprecipitation and reporter assays identified PU.1 motif sequences near Cebpa and Cbfb that are co-occupied by PU.1 and GATA-1 in the leukemic blasts. Significant derepression of Cebpa and Cbfb is achieved in MEL cells by either activation of PU.1 or knockdown of GATA-1. Furthermore, transcriptional regulation of these loci by manipulating the levels of PU.1 and GATA-1 involves quantitative increases in a transcriptionally active chromatin mark: acetylation of histone H3K9. Collectively, we show that either activation of PU.1 or inhibition of GATA-1 efficiently reverses the transcriptional block imposed by GATA-1 and leads to the activation of a myeloid transcriptional program directed by PU.1.

000      
04505naa a2200649 a 4500
001      
bmc12009041
003      
CZ-PrNML
005      
20140918092820.0
008      
120319s2009 xxu eng||
009      
AR
040    __
$d ABA008 $a ABA008 $b cze
041    0_
$a eng
044    __
$a xxu
100    1_
$a Burda, Pavel $7 xx0172028 $u Institute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
245    10
$a PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation / $c Pavel Burda, Nikola Curik, Juraj Kokavec, Petra Basova, Dana Mikulenkova, Arthur I. Skoultchi, Jiri Zavadil, Tomas Stopka
520    9_
$a Hematopoietic transcription factors GATA-1 and PU.1 bind each other on DNA to block transcriptional programs of undesired lineage during hematopoietic commitment. Murine erythroleukemia (MEL) cells that coexpress GATA-1 and PU.1 are blocked at the blast stage but respond to molecular removal (downregulation) of PU.1 or addition (upregulation) of GATA-1 by inducing terminal erythroid differentiation. To test whether GATA-1 blocks PU.1 in MEL cells, we have conditionally activated a transgenic PU.1 protein fused with the estrogen receptor ligand-binding domain (PUER), resulting in activation of a myeloid transcriptional program. Gene expression arrays identified components of the PU.1-dependent transcriptome negatively regulated by GATA-1 in MEL cells, including CCAAT/enhancer binding protein alpha (Cebpa) and core-binding factor, beta subunit (Cbfb), which encode two key hematopoietic transcription factors. Inhibition of GATA-1 by small interfering RNA resulted in derepression of PU.1 target genes. Chromatin immunoprecipitation and reporter assays identified PU.1 motif sequences near Cebpa and Cbfb that are co-occupied by PU.1 and GATA-1 in the leukemic blasts. Significant derepression of Cebpa and Cbfb is achieved in MEL cells by either activation of PU.1 or knockdown of GATA-1. Furthermore, transcriptional regulation of these loci by manipulating the levels of PU.1 and GATA-1 involves quantitative increases in a transcriptionally active chromatin mark: acetylation of histone H3K9. Collectively, we show that either activation of PU.1 or inhibition of GATA-1 efficiently reverses the transcriptional block imposed by GATA-1 and leads to the activation of a myeloid transcriptional program directed by PU.1.
536    __
$c Grant Number: HL 78381 (United States NHLBI NIH HHS)
536    __
$c Grant Number: R01 CA016368-26 (United States NCI NIH HHS)
590    __
$a bohemika - dle Pubmed
650    02
$a proteiny vázající zesilovač transkripce CCAAT $x genetika $x metabolismus $7 D022762
650    02
$a buněčná diferenciace $x genetika $7 D002454
650    02
$a nádorová transformace buněk $x genetika $x metabolismus $7 D002471
650    02
$a protein CBFB $x genetika $x metabolismus $7 D050658
650    02
$a transkripční faktor GATA1 $x genetika $x metabolismus $7 D050982
650    02
$a regulace genové exprese u nádorů $x genetika $7 D015972
650    02
$a HeLa buňky $7 D006367
650    02
$a histony $x genetika $x metabolismus $7 D006657
650    02
$a lidé $7 D006801
650    02
$a leukemie $x genetika $x metabolismus $x patofyziologie $7 D007938
650    02
$a myeloidní buňky $x metabolismus $7 D022423
650    02
$a protoonkogenní proteiny $x genetika $7 D011518
650    02
$a RNA interference $7 D034622
650    02
$a malá interferující RNA $7 D034741
650    02
$a rekombinantní fúzní proteiny $x genetika $x metabolismus $7 D011993
650    02
$a regulační elementy transkripční $x genetika $7 D050436
650    02
$a represorové proteiny $x genetika $x metabolismus $7 D012097
650    02
$a trans-aktivátory $x genetika $7 D015534
650    02
$a aktivace transkripce $x genetika $7 D015533
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Čuřík, Nikola. $7 xx0230099 $u Institute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Kokavec, Juraj. $7 _AN046347 $u Institute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Bašová, Petra. $7 _AN047591 $u Institute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
700    1_
$a Mikulenková, Dana. $7 xx0182877 $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Skoultchi, A. I. $u Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, USA
700    1_
$a Zavadil, Jiří $7 xx0104593 $u Department of Pathology, NYU Cancer Institute and Center for health Informatics and Bioinformatics, New York Langone Medical Center, New York, USA
700    1_
$a Stopka, Tomáš $7 xx0101300 $u Institute of Pathological Physiology and Center of Experimental Hematology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; First Medical Department, General Faculty Hospital, Prague, Czech Republic
773    0_
$t Molecular cancer research $p Mol Cancer Res $g Roč. 7, č. 10 (2009), s. 1693-1703 $x 1541-7786 $w MED00007101
910    __
$a ABA008 $b x $y 4 $z 0
990    __
$a 20120319150919 $b ABA008
991    __
$a 20140918093233 $b ABA008
999    __
$a ok $b bmc $g 902265 $s 765947
BAS    __
$a 3
BMC    __
$a 2009 $b 7 $c 10 $d 1693-1703 $i 1541-7786 $m Molecular cancer research $x MED00007101 $n Mol Cancer Res
GRA    __
$a NR9021 $p MZ0
GRA    __
$a NS10310 $p MZ0
LZP    __
$a 2012-1Q10/

Find record

Citation metrics

Archiving options